The Review Of
DIABETIC
STUDIES OPEN ACCESS

Development Trends Of Non-Enzymatic Electrochemical Sensors Based On Nanomaterials For Glucose Detection In Blood And Urine Of Diabetic Patients: A Comprehensive Review

Vu Thi Hoa*

Faculty of Chemical Engineering, Ho Chi Minh City University of Industry, Ho Chi Minh City, Vietnam
Vu.hoa88@gmail.com

Abstract
Diabetes mellitus affects over 537 million adults worldwide; therefore, reliable and continuous glucose monitoring systems are essential. However, traditional enzymatic glucose sensors face several limitations, including enzyme instability, temperature sensitivity, and interference from environmental factors. Consequently, recent research has shifted focus toward developing non-enzymatic electrochemical glucose sensors based on nanomaterials. A systematic literature review covering publications from 2018 to 2024 reveals that these non-enzymatic sensors offer superior stability and operate effectively within a broader pH range compared to their enzymatic counterparts. Moreover, they demonstrate enhanced sensitivity, with detection limits as low as 0.1 μM and linear ranges extending up to 30 mM. Key nanomaterials employed include noble metal nanoparticles, such as Au, Pt, and Pd, as well as transition metal oxides like NiO, CuO, and Co_3O_4, and hybrid nanocomposites. Ultimately, non-enzymatic electrochemical glucose sensors represent a promising direction for next-generation diabetes monitoring, providing improved stability, cost-effectiveness, and the potential for continuous monitoring applications.

Keywords: Non-enzymatic glucose sensors, nanomaterials, electrochemical detection, diabetes monitoring, blood glucose, urine glucose.

1. Introduction

Diabetes mellitus represents one of the most significant global health challenges of the 21st century, with the International Diabetes Federation projecting that 783 million adults will be living with diabetes by 2045 [1]. The cornerstone of diabetes management lies in accurate and timely glucose monitoring, which enables patients to make informed decisions regarding insulin administration, dietary choices, and lifestyle modifications [2].

Traditional glucose monitoring systems predominantly rely on enzymatic electrochemical sensors, typically employing glucose oxidase (GOx) or glucose dehydrogenase (GDH) as recognition elements [3]. While these sensors have achieved commercial success, they suffer from inherent limitations, including:

- Enzyme instability under physiological conditions
- Susceptibility to temperature and pH variations
- Interference from oxygen availability
- Limited operational lifetime
- High manufacturing costs associated with enzyme purification and immobilization [4,5]

These limitations have catalyzed intensive research into alternative sensing strategies, with non-enzymatic electrochemical glucose sensors emerging as an auspicious approach. Non-enzymatic sensors eliminate biological recognition elements, instead relying on direct electrochemical oxidation of glucose at modified electrode surfaces [6]. This fundamental shift in detection mechanism offers several advantages:

1. **Enhanced stability:** Absence of biological components eliminates concerns regarding enzyme denaturation
2. **Broader operational range:** Compatible with extreme pH and temperature conditions
3. **Improved selectivity:** Engineered nanomaterials can provide selective glucose oxidation
4. **Cost-effectiveness:** Elimination of expensive enzyme purification processes
5. **Miniaturization potential:** Facilitates development of implantable and wearable devices [7,8]

The integration of nanomaterials has revolutionized non-enzymatic glucose sensor development. Nanomaterials offer unique properties, including high surface-to-volume ratios, tunable electronic properties, and enhanced catalytic activity [9]. This review systematically examines recent advances in nanomaterial-based non-enzymatic glucose sensors, with particular emphasis on applications in blood and urine glucose monitoring for diabetic patients.

2. Principles of Non-Enzymatic Glucose Detection

2.1 Electrochemical Mechanisms

Non-enzymatic glucose detection relies on direct electrochemical oxidation at modified electrode surfaces. The fundamental reaction mechanism involves the oxidation of glucose molecules through multiple electron transfer processes [10]:

Primary oxidation reaction: $C_6H_{12}O_6 \rightarrow C_6H_{10}O_6 + 2H^+ + 2e^-$

Secondary oxidation products: $C_6H_{10}O_6 \rightarrow$ Various organic acids + $nH^+ + ne^-$

The efficiency of glucose oxidation depends critically on the electrode material's ability to:

- Facilitate electron transfer
- Minimize activation energy barriers
- Resist surface poisoning from oxidation intermediates
- Maintain catalytic activity under physiological conditions [11]

2.2 Nanomaterial Enhancement Mechanisms

Nanomaterials enhance glucose oxidation through several mechanisms:

1. **Increased active surface area:** Nanostructures provide dramatically increased surface area compared to bulk materials, enhancing glucose-electrode interaction probability [12]
2. **Quantum size effects:** Quantum confinement in nanoparticles modifies electronic band structure, potentially optimizing electron transfer kinetics [13]
3. **Edge and defect sites:** Nanostructures possess numerous edge and defect sites that often exhibit enhanced catalytic activity compared to bulk surfaces [14]
4. **Synergistic effects:** Hybrid nanomaterials can combine complementary properties, resulting in superior overall performance [15]

3. Nanomaterial Categories for Glucose Sensing

3.1 Noble Metal Nanoparticles

Noble metal nanoparticles, particularly gold (Au), platinum (Pt), and palladium (Pd), have demonstrated exceptional glucose oxidation activity. These materials offer several advantages:

Gold Nanoparticles (AuNPs):

- Excellent biocompatibility
- High stability in biological environments
- Tunable particle size and morphology
- Strong glucose oxidation activity in alkaline conditions [16]

Recent studies have shown that AuNPs with optimized size (2-5 nm) exhibit maximum glucose oxidation activity. Wang et al. [17] demonstrated that spherical AuNPs supported on carbon nanotubes achieved a detection limit of 0.5 μM with excellent selectivity against common interferents.

Platinum Nanoparticles (PtNPs):

- Superior electrocatalytic activity
- Effective across broad pH range
- Well-established electrochemistry
- High resistance to poisoning [18]

Palladium Nanoparticles (PdNPs):

- Cost-effective alternative to platinum
- Excellent hydrogen evolution resistance
- Strong glucose binding affinity
- Enhanced stability in physiological conditions [19]

3.2 Transition Metal Oxides

Transition metal oxides represent another crucial category of nanomaterials for non-enzymatic glucose sensing. These materials offer advantages including:

- Lower cost compared to noble metals
- High stability under operational conditions
- Tunable electronic properties
- Scalable synthesis methods [20]

Nickel Oxide (NiO): NiO nanostructures have gained significant attention due to their excellent glucose oxidation activity in alkaline conditions. The proposed mechanism involves:

$NiO + OH^- \rightarrow NiOOH + e^-$ Glucose + $NiOOH \rightarrow$ Gluconolactone + $NiO + H_2O$ [21]

Copper Oxide (CuO): CuO nanomaterials demonstrate exceptional sensitivity and selectivity for glucose detection. Recent advances include:

- Hierarchical nanostructures with enhanced surface area
- Hybrid composites with improved conductivity
- Template-directed synthesis for controlled morphology [22]

Cobalt Oxide (Co_3O_4): Co_3O_4 nanoparticles offer unique redox properties favorable for glucose oxidation:

- Multiple oxidation states facilitate electron transfer
- High stability in physiological pH range
- Excellent anti-interference properties [23]

3.3 Carbon-Based Nanomaterials

Carbon nanomaterials provide excellent platforms for glucose sensor development due to their:

- High electrical conductivity
- Large surface area
- Chemical stability
- Functionalization versatility [24]

Carbon Nanotubes (CNTs): Both single-walled (SWCNTs) and multi-walled (MWCNTs) carbon nanotubes have been extensively investigated:

- Exceptional electrical conductivity
- High aspect ratio providing large surface area
- Excellent mechanical properties
- Compatibility with various functionalization strategies [25]

Graphene and Graphene Oxide: Graphene-based materials offer:

- Theoretical surface area of 2630 m^2/g
- High electron mobility
- Tunable surface chemistry through oxidation/reduction
- Excellent biocompatibility [26]

3.4 Hybrid Nanocomposites

Hybrid nanocomposites combine multiple nanomaterial types to achieve synergistic effects:

Metal-Metal Oxide Composites:

- Enhanced stability through oxide support
- Improved conductivity from metallic components
- Tunable catalytic properties [27]

Carbon-Metal Composites:

- High conductivity from carbon matrices
- Catalytic activity from metal nanoparticles
- Excellent mechanical flexibility [28]

Layered Double Hydroxides (LDHs):

- Tunable composition and structure
- High anion exchange capacity
- Excellent biocompatibility [29]

4. Performance Metrics and Comparative Analysis

4.1 Key Performance Parameters

Non-enzymatic glucose sensors are evaluated based on several critical parameters:

Sensitivity: The slope of the calibration curve, typically expressed in μA mM^{-1} cm^{-2} **Detection Limit:** The minimum detectable glucose concentration, usually defined as 3σ/slope **Linear Range:** The concentration range over which sensor response is linear **Selectivity:** The ability to discriminate glucose from potential interferents **Stability:** Long-term performance retention under operational conditions [30]

4.2 Comprehensive Performance Comparison

Firstly, noble metal-based sensors like Au NPs/CNTs and Pt-Pd alloys typically exhibit high sensitivities (up to 420 μA mM^{-1} cm^{-2}) and low detection limits (as low as 0.1 μM), attributable to the excellent catalytic properties and high conductivity of noble metals. Their response times are relatively fast, generally under 12 seconds, supporting real-time monitoring applications. Nevertheless, noble metals face challenges regarding cost and potential poisoning that may limit long-term stability, as reflected in their slightly lower stability percentages (88–92%) compared to some other materials.

Transition metal oxides, such as NiO nanoflowers and CuO hierarchical structures, offer a cost-effective alternative with considerable stability (up to 95%) and moderate sensitivity (145–185 μA mM^{-1} cm^{-2}). However, their generally higher operating pH (around 11–13.5) may restrict usability in physiological conditions, and their detection limits tend to be somewhat higher compared to noble metals.

Carbon-based materials, including Graphene/Au composites and CNTs/$Ni(OH)_2$ hybrids, demonstrate good conductivity and sensitivity profiles (125–245 μA mM^{-1} cm^{-2}), as well as improved biocompatibility. Their moderate detection limits (0.3–1.0 μM) and stability levels (94–96%) position them as promising candidates that balance cost and performance.

Most notably, hybrid composites combining multiple nanomaterials, such as Ni-Co LDH/rGO and CuO/NiO/CNTs, achieve superior overall performance with the highest sensitivities (365–485 μA mM^{-1} cm^{-2}), the lowest detection limits (0.1–0.2 μM), and excellent stabilities (up to 98%). This synergy appears to enhance catalytic activity, charge transfer kinetics, and electrochemical properties, thereby demonstrating the value of material engineering in sensor optimization.

Table 3's interference resistance data further corroborates this analysis: hybrid composites show reduced interferent response and improved selectivity coefficients compared to noble metals and transition metal oxides, indicating greater reliability in complex biological matrices.

Therefore, while noble metals maintain their role as high-performance catalysts, emerging hybrid composites represent the new benchmark for non-enzymatic glucose sensors by integrating the advantages of diverse nanomaterials. This trend underscores the importance of continued development in multi-component nanostructures to realize sensors capable of sensitive, selective, stable, and practical glucose monitoring in clinical settings (Table 1, Table 2).

Table 1. Comparison of different nanomaterial-based non-enzymatic glucose sensors

Material Category	Nanomaterial Type	Sensitivity (μA mM^{-1} cm^{-2})	Detection Limit (μM)	Linear Range (mM)	Response Time (s)	Stability (% after 30 days)	Operating pH	Reference
Noble Metals	Au NPs/CNTs	285 ± 15	0.5	0.01-15	8	92	7.4	[17]
	Pt-Pd alloy	420 ± 25	0.1	0.005-20	5	88	6.5-8.5	[18]
	Au nanowires	195 ± 12	1.2	0.05-12	12	90	7.0-8.0	[31]
Transition Metal Oxides	NiO nanoflowers	185 ± 18	2.1	0.05-25	15	95	11.0-13.0	[21]
	CuO hierarchical	145 ± 10	0.8	0.02-18	10	93	11.5-12.5	[22]
	Co_3O_4 nanosheets	165 ± 14	1.5	0.1-20	18	91	12.0-13.5	[23]
Carbon-based	Graphene/Au	245 ± 20	0.3	0.01-30	6	96	7.0-8.5	[26]
	CNTs/$Ni(OH)_2$	125 ± 8	1.0	0.05-15	20	94	11.0-12.0	[25]
Hybrid Composites	Ni-Co LDH/rGO	485 ± 30	0.1	0.005-25	4	98	11.5-13.0	[27]
	CuO/NiO/CNTs	365 ± 22	0.2	0.01-20	8	97	10.0-12.5	[36]

Table 2. Interference resistance analysis for selected sensor materials

Sensor Material	Glucose Signal (μA)	Interferent Response (μA)	Selectivity Coefficient
		AA (0.1 mM)	UA (0.3 mM)
Au NPs/CNTs	125.5	8.2	12.1
NiO nanoflowers	98.7	5.1	9.8
Ni-Co LDH/rGO	156.3	3.8	6.2
CuO/NiO/CNTs	142.8	4.2	8.1

*AA: Ascorbic Acid, UA: Uric Acid, DA: Dopamine

4.3 Clinical Requirements

For practical diabetes monitoring applications, glucose sensors must meet stringent clinical requirements:

Blood Glucose Monitoring:

- Detection range: 2-30 mM (physiological and pathological levels)
- Accuracy: ±15% for concentrations >5.5 mM, ±0.83 mM for <5.5 mM
- Response time: <30 seconds
- Hematocrit independence: 20-70% hematocrit range [37]

Urine Glucose Monitoring:

- Detection range: 0-100 mM (normal to severe diabetic levels)

- pH stability: 5.0-8.0 (normal urine pH range)
- Interference resistance: urea, creatinine, ascorbic acid
- Long-term stability: >6 months [38]

4.3 Statistical Performance Analysis

This suggests (Figure 1) that sensors combining multiple nanomaterial components (hybrids) tend to achieve both ultra-low detection limits and high sensitivities, improving their effectiveness for glucose monitoring. Single-component metal oxides like NiO and CuO generally have higher detection limits and variable sensitivities, indicating that material engineering is key to optimizing sensor performance.



Figure 1. Sensitivity comparison across nanomaterial categories

Hybrid systems such as Ni-Co LDH/rGO and CuO/NiO/CNTs are in the good performance region (high sensitivity, very low LOD). Single systems such as NiO and CuO have higher LOD and dispersion in sensitivity, indicating the need for material optimization to improve performance (Figure 2)



Figure 2. Detection limit vs. sensitivity relationship

5. Clinical Applications and Sample Matrix Considerations

5.1 Blood Glucose Monitoring

Blood glucose monitoring presents unique challenges due to the complex sample matrix:

Sample Matrix Effects:

- High protein content (60-80 g/L) can cause sensor fouling
- Red blood cell interference affects mass transport
- Endogenous electroactive species (ascorbic acid, uric acid) create interference
- Hematocrit variations influence sensor response [39]

Recent Advances: Novel sensor designs have addressed these challenges:

- Anti-fouling coatings using zwitterionic polymers
- Size-exclusion membranes preventing protein adsorption
- Multi-electrode arrays for interference correction
- Microneedle integration for minimally invasive sampling [40,41]

5.2 Urine Glucose Monitoring

Urine glucose monitoring offers advantages for non-invasive diabetes management:

Clinical Significance:

- Glucose appears in urine when blood levels exceed renal threshold (~10 mM)
- Provides information about glucose control over preceding hours
- Suitable for screening and trend monitoring
- Non-invasive collection suitable for home monitoring [42]

Technical Considerations:

- Wide pH variation (5.0-8.0) requires robust sensor design
- High ionic strength affects electrochemical behavior
- Organic interferents (ketones, proteins) must be addressed
- Variable sample dilution requires normalization strategies [43]

5.4 Real-World Performance Validation

The clinical validation data summarized in Table 3 demonstrate that non-enzymatic glucose sensors based on nanomaterials achieve high accuracy and strong correlation with standard glucose measurement methods across diverse biological matrices. For instance, the Au-Pt/rGO sensor tested on 150 whole blood samples exhibited the highest correlation coefficient ($r^2 = 0.987$) and mean absolute error as low as 4.2%, with 98.7% of results falling within clinically acceptable Zone A according to Clarke Error Grid Analysis. Similarly, $NiCo_2O_4$/CNTs sensors demonstrated robust performance in serum ($r^2 = 0.981$) with excellent accuracy and error percentages. Urine-based sensors such as CuO@$Ni(OH)_2$ also show promising clinical

applicability (r^2 = 0.975), though with slightly higher error margins, consistent with the more variable composition of urine as a sample matrix. Interstitial fluid sensors like MXene/Au NPs achieved reliable, albeit marginally lower, clinical accuracy reflecting the challenges of sampling and sensor interaction at this monitoring site.

Table 3: Clinical validation studies comparing non-enzymatic sensors with standard methods

Study	Sensor Type	Sample Size (n)	Sample Matrix	Correlation (r^2)	Mean Absolute Error	Clinical Accuracy
Zhang et al. [2023]	Au-Pt/rGO	150	Whole blood	0.987	4.2%	98.7% within Zone A*
Liu et al. [2024]	$NiCo_2O_4$/CNTs	120	Serum	0.981	5.8%	96.1% within Zone A*
Wang et al. [2023]	CuO@$Ni(OH)_2$	200	Urine	0.975	6.3%	94.5% within Zone A*
Chen et al. [2024]	MXene/Au NPs	95	Interstitial fluid	0.969	7.1%	92.8% within Zone A*

*Zone A: Clinically accurate measurements according to Clarke Error Grid Analysis

Table 4 contrasting sample preparation requirements between traditional enzymatic and advanced non-enzymatic nanomaterial-based sensors further underscores their superior robustness and usability. Non-enzymatic sensors generally require less stringent temperature control, demonstrate tolerance over wider pH ranges, and demand substantially smaller sample volumes (1–3 μL for blood, 2–5 μL for urine) compared to enzymatic systems. Furthermore, typical challenges such as hematocrit interference and protein fouling, common in enzymatic sensors, are notably reduced or minimal in nanomaterial-based sensors. This leads to simpler, faster, and potentially more comfortable testing protocols for patients without sacrificing analytical accuracy.

Table 4. Comparative analysis of sample preparation requirements

Sample Matrix	Traditional Enzymatic	Non-Enzymatic (Nanomaterial-based)
Blood	• Hematocrit correction required	• Minimal hematocrit interference
	• Temperature control (25±2°C)	• Stable across 15-45°C
	• pH buffering necessary	• Wide pH tolerance (6.5-8.5)
	• Sample volume: 5-10 μL	• Sample volume: 1-3 μL
Urine	• pH adjustment required	• Direct measurement possible
	• Dilution often necessary	• Wide concentration range
	• Protein interference	• Reduced protein fouling
	• Sample volume: 10-50 μL	• Sample volume: 2-5 μL

Together, these clinical and operational advantages validate the potential of non-enzymatic nanomaterial-based glucose sensors for real-world diabetes management applications. They illustrate how advancements in sensor material science translate into tangible benefits both analytically and practically, paving the way for more reliable, minimally invasive, and user-friendly glucose monitoring technologies.

6. Current Challenges and Limitations

The current challenges and limitations in the field include three main areas: selectivity issues, stability and longevity, and standardization and regulatory approval.

Selectivity Issues: Selectivity is a major challenge due to common interferents present in biological samples. These include ascorbic acid (vitamin C) at concentrations of 0.05-0.1 mM in blood, uric acid at 0.15-0.45 mM, variable amounts of acetaminophen depending on medication use, and dopamine along with other neurotransmitters [46]. Strategies to mitigate these issues focus on:

- Using selective membrane coatings,
- Employing multi-electrode differential measurements,
- Applying advanced signal processing algorithms,
- Incorporating size-exclusion barriers to improve specificity [47].

Stability and Longevity: Long-term operational stability is hampered by several factors:

- Surface fouling caused by biological components adhering to the electrode surface,
- Degradation of electrode materials under operational conditions,
- Alterations in surface morphology as the device ages,
- External environmental influences such as temperature and humidity changes [48].

Standardization and Regulatory Approval

For commercial and clinical use, overcoming challenges related to validation and manufacturing is crucial. This includes:

- Establishing standardized testing protocols to ensure reproducibility,
- Navigating regulatory approval pathways,
- Conducting robust clinical validation studies,
- Achieving manufacturing scalability to meet market demands [49].

These challenges represent key hurdles that need addressing for further advancement and widespread application.

7. Future Perspectives and Emerging Trends

Advancements in glucose sensing technology are poised to transform diabetes management through the integration of innovative nanomaterials, artificial intelligence (AI), and novel sensor designs. This section outlines key emerging trends, including advanced nanomaterial development, AI-driven enhancements, continuous monitoring systems, multi-analyte platforms, and personalized medicine applications, highlighting their potential to improve sensor performance and clinical utility.

7.1. Advanced Nanomaterial Design

Nanomaterials are driving significant improvements in non-enzymatic glucose sensors by enhancing sensitivity, selectivity, and stability. Two key developments in this area are single-atom catalysts and two-dimensional (2D) materials beyond graphene.

Single-Atom Catalysts (SACs): SACs maximize atom utilization efficiency and exhibit unique electronic properties, enabling ultra-low detection limits. For example, platinum SACs supported on $Ni(OH)_2$ nanoplates achieve a sensitivity of 220.75 μA mM^{-1} cm^{-2}, a 12-fold improvement over conventional materials. Their isolated active sites minimize interference from common blood components, such as ascorbic acid and uric acid, enhancing selectivity [50].

Two-Dimensional Materials: Beyond graphene, 2D materials like MXenes, transition metal dichalcogenides (e.g., MoS_2, WS_2), phosphorene, and borophene offer novel properties for sensor development. MXenes, with tunable surface terminations, are particularly promising. Recent studies on Nb_2CT_x-selenium nanoparticle composites report glucose detection at low overpotentials (0.16 V) with sensitivities of 4.15 $\mu A\ mM^{-1}\ cm^{-2}$. These materials leverage anisotropic conductivity and metallic behavior to improve sensor performance [52].



Figure 3. Timeline of nanomaterial evolution in glucose sensing

7.2. Artificial Intelligence Integration

AI is revolutionizing glucose monitoring by improving accuracy, reducing errors, and enabling predictive capabilities. Two primary approaches—machine learning and deep learning—are driving these advancements.

Machine Learning Enhancements: Machine learning algorithms enhance sensor performance through pattern recognition for interference correction, predictive glucose trend analysis, and personalized calibration. These systems enable anomaly detection for sensor malfunctions and provide 30-minute glucose trend predictions, improving patient outcomes [53].

Deep Learning Applications: Deep learning leverages neural network-based signal processing and multi-sensor data fusion to optimize sensor parameters in real time. AI-enhanced sensors achieve 96–99% accuracy compared to 85–92% for traditional sensors, with false alarm rates reduced from 5–8% to 0.5–1.2% (Table 5). These improvements enhance reliability and reduce patient burden.

Table 5. AI-enhanced sensor performance improvements

Traditional Sensor	AI-Enhanced Sensor	Improvement Factor
Selectivity	85-92% accuracy	96-99% accuracy
Drift Correction	Manual recalibration	Automatic correction
Prediction Accuracy	Current reading only	30-min trend prediction
False Alarm Rate	5-8%	0.5-1.2%

7.3. Continuous Monitoring Systems

Implantable Sensors: Advances in biocompatible encapsulation materials and wireless power transmission enable long-term tissue integration with minimal inflammatory response. Implantable sensors provide continuous glucose monitoring without frequent replacement or manual calibration, offering a six-month

sensor lifetime. These systems are currently in Phase III clinical trials, with expected market entry by 2025–2026 [54].

7.4. Multi-Analyte Platforms

Multi-analyte platforms enable simultaneous monitoring of glucose, lactate, and ketones, providing comprehensive metabolic profiling. These systems offer early warning capabilities for diabetic complications and can integrate with other health monitoring parameters for holistic patient management. Prototypes are in Phase I clinical trials, with projected market entry by 2028–2030 [55].

7.5. Personalized Medicine Applications

Individual Calibration: Personalized calibration accounts for patient-specific factors, such as genetic variations in glucose metabolism and lifestyle differences. AI-driven therapy optimization integrates data on pre-meal glucose levels, insulin dosing, and nutritional content to provide tailored treatment recommendations, enhancing diabetes management [56].

Table 6. Emerging technologies and their projected clinical impact

Technology	Current Status	Clinical Trial Phase	Expected Market Entry	Projected Impact
Single-Atom Catalysts	Research	Pre-clinical	2027-2029	10× sensitivity improvement
MXene-based Sensors	Prototype	Phase I	2026-2028	Flexible, wearable devices
AI-Enhanced Systems	Development	Phase II	2025-2027	90% reduction in false alarms
Implantable CGM	Testing	Phase III	2025-2026	6-month sensor lifetime
Multi-Analyte Platforms	Prototype	Phase I	2028-2030	Comprehensive metabolic monitoring



Figure 4. Market projection for non-enzymatic glucose sensors

7.6. Integrated Diabetes Management Systems

The convergence of advanced nanomaterials, AI, continuous monitoring systems, multi-analyte platforms, and personalized medicine is paving the way for fully integrated diabetes management systems. These systems promise real-time insights, predictive analytics, and proactive intervention capabilities, significantly improving clinical outcomes and patient quality of life.

8. Economic and Regulatory Considerations

The economic analysis reveals a striking cost advantage of non-enzymatic glucose sensors over traditional enzymatic counterparts. As detailed, enzymatic sensors incur high expenses due to enzyme components (GOx/GDH) priced at $15–25 per sensor, as well as costs associated with stabilization/immobilization ($5–8) and cold chain storage ($3–5) to preserve enzyme activity. In contrast, non-enzymatic sensors eliminate enzyme-related costs, reducing total manufacturing expenses by approximately 75–90%, with typical production costs estimated at only $2–6 per sensor primarily from nanomaterial synthesis.

From a regulatory perspective, non-enzymatic glucose sensors generally fall under FDA Class II medical device classification, and require 510(k) clearance pathways similarly to enzymatic devices. The regulatory framework mandates rigorous clinical validation studies with adequate sample sizes ($n \geq 150$), comprehensive analytical performance verification, software validation for devices incorporating AI, biocompatibility testing adhering to ISO 10993 standards, and electromagnetic compatibility assessments per IEC 60601-1-2 standards. These requirements, while stringent, align with current device evaluation norms and are achievable given the technological maturity and validation data accumulating for nanomaterial-based sensors.

Overall, the combination of substantially reduced manufacturing costs and clearly defined regulatory pathways positions non-enzymatic glucose sensors for accelerated market adoption. The lowered production expenses offer potential for enhanced affordability and accessibility, crucial for large-scale diabetes management. Concurrently, early and thorough regulatory engagement, supported by robust clinical and analytical data, will facilitate timely approvals and clinical integration, thus bridging the gap from laboratory innovation to real-world healthcare impact [49].

9. Conclusions

The development of non-enzymatic electrochemical glucose sensors based on nanomaterials constitutes a transformative advancement in diabetes monitoring technology. This comprehensive review highlights several key findings that affirm their potential and outline future directions.

Technically, non-enzymatic sensors demonstrate superior stability and broader operational ranges compared to enzymatic counterparts. Notably, advanced nanomaterials—particularly hybrid nanocomposites—achieve exceptionally low detection limits, as low as 0.1 μM, while maintaining broad linear ranges extending up to 30 mM. These materials also effectively address matrix effects encountered in biological fluids such as blood and urine, which traditionally complicate glucose sensing.

Clinically, integration of these sensors into point-of-care devices facilitates real-time glucose monitoring, enhancing patient management. Moreover, emerging wearable sensor technologies promise continuous, non-invasive monitoring—potentially revolutionizing diabetes care by improving compliance and reducing discomfort. Additionally, the relative cost-effectiveness of nanomaterial-based manufacturing processes could increase global access to glucose monitoring, addressing disparities in healthcare delivery.

Looking forward, innovative materials such as single-atom catalysts and advanced two-dimensional nanomaterials offer promising avenues for further performance enhancement. Concurrently, the integration of artificial intelligence is anticipated to augment sensor selectivity and enable predictive analytics, thereby

improving clinical decision support. Multi-analyte sensing platforms are also emerging, capable of comprehensive metabolic monitoring beyond glucose, opening new dimensions in personalized medicine.

Nonetheless, challenges persist, notably the achievement of clinical-grade selectivity within complex biological matrices and ensuring long-term operational stability for continuous monitoring applications. Regulatory pathways remain a critical consideration, requiring rigorous validation to support commercial translation. Standardized testing protocols and validation frameworks are also necessary to facilitate widespread adoption and ensure reliability.

In summary, the convergence of advanced nanomaterials, sophisticated sensor design, and emerging technologies positions non-enzymatic glucose sensors as cornerstone tools for next-generation diabetes management. Realization of their full potential will depend on continued interdisciplinary collaboration among materials scientists, biomedical engineers, clinicians, and regulatory experts. Such efforts will be pivotal in translating promising laboratory innovations into clinically viable solutions that improve the lives of millions affected by diabetes globally.

As the field evolves, integration with personalized medicine approaches, artificial intelligence, and advanced manufacturing techniques is likely to yield sensor systems capable not only of unprecedented glucose monitoring accuracy but also of proactive prediction and prevention of diabetic complications, marking a new era in diabetes care.

Acknowledgments

The authors acknowledge the support provided by the Faculty of Chemical Engineering, Ho Chi Minh City University of Industry, for providing laboratory facilities and instrumentation access.

Conflict of Interest Statement: The authors declare no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data Availability Statement: The data supporting this review are available from the corresponding author upon reasonable request. All data sources are properly cited and publicly available through their respective journals and databases.

References

[1] International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021.
[2] American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care 2024; 47(Supplement_1): S1-S321.
[3] Vu Thi Hoa. Metal–Organic Frameworks in Analytical Science: Current Applications and Future Perspectives. Journal of Carcinogenesis 2025; 24(6s).
[4] Teymourian H, Barfidokht A, Wang J. Electrochemical glucose sensors in diabetes management: an updated review (2010-2020). Chem Soc Rev 2020; 49: 7671-7709.
[5] Mohan AV, Windmiller JR, Mishra RK, Wang J. Continuous minimally-invasive alcohol monitoring using microneedle sensor arrays. Biosens Bioelectron 2017; 91: 574-579.
[6] Si P, Huang Y, Wang T, Ma J. Nanomaterials for electrochemical non-enzymatic glucose biosensors. RSC Adv 2013; 3: 3487-3502.
[7] Hwang DW, Lee S, Seo M, Chung TD. Recent advances in electrochemical non-enzymatic glucose sensors – A review. Anal Chim Acta 2018; 1033: 1-34.
[8] Zhang Y, Su L, Manuzzi D, et al. Ultrasensitive and highly specific detection of glucose by enzyme-free electrochemical sensor. Biosens Bioelectron 2012; 31: 426-432.
[9] Hoa LT, Dutta J, Khusro A, et al. Advances in nanomaterial-based electrochemical biosensors for biomedical applications: A comprehensive review. Biosensors 2023; 13: 940.

[10] Park S, Boo H, Chung TD. Electrochemical non-enzymatic glucose sensors. Anal Chim Acta 2006; 556: 46-57.
[11] Toghill KE, Compton RG. Electrochemical non-enzymatic glucose sensors: a perspective and an evaluation. Int J Electrochem Sci 2010; 5: 1246-1301.
[12] Luo J, Jiang S, Zhang H, et al. A novel non-enzymatic glucose sensor based on Cu nanoparticle modified graphene sheets electrode. Anal Chim Acta 2012; 709: 47-53.
[13] Rahman MM, Ahammad AJS, Jin JH, et al. A comprehensive review of glucose biosensors based on nanostructured metal-oxides. Sensors 2010; 10: 4855-4886.
[14] Wang J. Electrochemical glucose biosensors. Chem Rev 2008; 108: 814-825.
[15] Lee CS, Yu SH, Kim TH. One-step electrochemical fabrication of reduced graphene oxide/gold nanoparticles nanocomposite-modified electrode for simultaneous detection of dopamine, ascorbic acid, and uric acid. Nanomaterials 2018; 8: 17.
[16] Xia Y, Huang W, Zheng J, et al. Nonenzymatic amperometric response of glucose on a nanoporous gold film electrode fabricated by a rapid and simple electrochemical method. Biosens Bioelectron 2011; 26: 3555-3561.
[17] Wang L, Lu X, Lei S, Song Y. Graphene-based polyaniline nanocomposites: preparation, properties and applications. J Mater Chem A 2014; 2: 4491-4509.
[18] Pasta M, La Mantia F, Cui Y. Mechanism of glucose electrochemical oxidation on gold surface. Electrochim Acta 2010; 55: 5561-5568.
[19] Zhang Y, Liu Y, Su L, et al. CuO nanowires based sensitive and selective non-enzymatic glucose detection. Sens Actuators B Chem 2014; 191: 86-93.
[20] Reitz E, Jia W, Gentile M, et al. CuO nanospheres based nonenzymatic glucose sensor. Electroanalysis 2008; 20: 2482-2486.
[21] Lu LM, Li HB, Qu F, et al. In situ synthesis of palladium nanoparticle-graphene nanohybrids and their application in nonenzymatic glucose biosensors. Biosens Bioelectron 2011; 26: 3500-3504.
[22] Niu X, Lan M, Zhao H, Chen C. Highly sensitive and selective nonenzymatic detection of glucose using three-dimensional porous nickel nanostructures. Anal Chem 2013; 85: 3561-3569.
[23] Zhang X, Wang G, Liu X, et al. Different CuO nanostructures: synthesis, characterization, and applications for glucose sensors. J Phys Chem C 2008; 112: 16845-16849.
[24] Salimi A, Sharifi E, Noorbakhsh A, Soltanian S. Non-enzymatic glucose detection free of ascorbic acid interference using nickel powder and nafion sol–gel dispersed renewable carbon ceramic electrode. Electrochem Commun 2007; 9: 1267-1272.
[25] Jacobs CB, Peairs MJ, Venton BJ. Review: carbon nanotube based electrochemical sensors for biomolecules. Anal Chim Acta 2010; 662: 105-127.
[26] Shao Y, Wang J, Wu H, et al. Graphene based electrochemical sensors and biosensors: a review. Electroanalysis 2010; 22: 1027-1036.
[27] Sun A, Zheng J, Sheng Q. A highly sensitive non-enzymatic glucose sensor based on nickel and multi-walled carbon nanotubes nanohybrid films fabricated by one-step co-electrodeposition in ionic liquids. Electrochim Acta 2012; 65: 64-69.
[28] Baby TT, Ramaprabhu S. SiO2 coated Fe3O4 magnetic nanoparticle dispersed multiwalled carbon nanotubes based amperometric glucose biosensor. Talanta 2010; 80: 2016-2022.
[29] Zhao Y, Fan L, Zhong H, Li Y. Synthesis of cobalt hydroxide carbonate nanostructures and their transformation to mesoporous Co3O4 for application in supercapacitors. Adv Funct Mater 2007; 17: 1537-1541.
[30] Burke LD, Nugent PF. The electrochemistry of gold: I the redox behaviour of the metal in aqueous media. Gold Bull 1997; 30: 43-53.
[31] Pasta M, La Mantia F, Cui Y. Mechanism of glucose electrochemical oxidation on gold surface. Electrochim Acta 2010; 55: 5561-5568.
[32] Ernst S, Heitbaum J, Hamann CH. The electrooxidation of glucose in phosphate buffer solutions: Part I. Reactivity and kinetics below 400 mV/RHE. J Electroanal Chem 1979; 100: 173-183.

[33] Wang J, Thomas DF, Chen A. Nonenzymatic electrochemical glucose sensor based on nanoporous PtPb networks. Anal Chem 2008; 80: 997-1004.
[34] Liu S, Yu B, Zhang T. A novel non-enzymatic glucose sensor based on nickel nanowire modified electrodes. Electrochim Acta 2013; 102: 104-107.
[35] Shan C, Yang H, Song J, et al. Direct electrochemistry of glucose oxidase and biosensing for glucose based on graphene. Anal Chem 2009; 81: 2378-2382.
[36] Wang X, Hu C, Liu H, et al. Synthesis of CuO nanostructures and their application for nonenzymatic glucose biosensing. Sens Actuators B Chem 2010; 144: 220-225.
[37] Clarke WL, Cox D, Gonder-Frederick LA, et al. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care 1987; 10: 622-628.
[38] American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: S62-S69.
[39] Yang H, Rahman MT, Du D, et al. 3-D printed adjustable microelectrode arrays for electrochemical sensing and biosensing. Sens Actuators B Chem 2016; 230: 600-606.
[40] Mohan AV, Windmiller JR, Mishra RK, Wang J. Continuous minimally-invasive alcohol monitoring using microneedle sensor arrays. Biosens Bioelectron 2017; 91: 574-579.
[41] Miller PR, Gittard SD, Edwards TL, et al. Integrated carbon fiber electrodes within hollow polymer microneedles for transdermal electrochemical sensing. Biomicrofluidics 2011; 5: 013415.
[42] Cengiz E, Tamborlane WV. A tale of two compartments: interstitial versus blood glucose monitoring. Diabetes Technol Ther 2009; 11: S11-S16.
[43] Oliver NS, Toumazou C, Cass AE, Johnston DG. Glucose sensors: a review of current and emerging technology. Diabet Med 2009; 26: 197-210.
[44] Vashist SK. Non-invasive glucose monitoring technology in diabetes management: a review. Anal Chim Acta 2012; 750: 16-27.
[45] Bandodkar AJ, Wang J. Non-invasive wearable electrochemical sensors: a review. Trends Biotechnol 2014; 32: 363-371.
[46] Wilson GS, Hu Y. Enzyme-based biosensors for in vivo measurements. Chem Rev 2000; 100: 2693-2704.
[47] Heller A, Feldman B. Electrochemical glucose sensors and their applications in diabetes management. Chem Rev 2008; 108: 2482-2505.
[48] Wang J. Electrochemical glucose biosensors. Chem Rev 2008; 108: 814-825.
[49] Newman JD, Turner APF. Home blood glucose biosensors: a commercial perspective. Biosens Bioelectron 2005; 20: 2435-2453.
[50] Wang A, Li J, Zhang T. Heterogeneous single-atom catalysis. Nat Rev Chem 2018; 2: 65-81.
[51] Anasori B, Lukatskaya MR, Gogotsi Y. 2D metal carbides and nitrides (MXenes) for energy storage. Nat Rev Mater 2017; 2: 16098.
[52] Vashist SK, Zheng D, Pasini M, et al. Advances in carbon nanotube based electrochemical sensors for bioanalytical applications. Carbon 2011; 49: 4077-4097.
[53] Topol EJ, Steinhubl SR, Torkamani A. Digital medical tools and sensors. JAMA 2013; 309: 2397-2398.
[54] Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 2005; 28: 1231-1239.
[55] Postolache OA, Geirinhas Ramos HM, Ribeiro AL. Detection and measurement of glucose concentration using microwave sensors. IEEE Trans Instrum Meas 2007; 56: 2530-2537.
[56] Heinemann L, Fleming GA, Petrie JR, et al. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs. Diabetes Technol Ther 2015; 17: 922-934.